to rituximab. 7 In contrast, a severe hypersensitiv ity reaction to ofatumumab has been observed in another patient with thrombocytopenic purpu ra who had previously suffered from rituximab associated anaphylaxis.
8 Here, we report 2 cas es of CLL patients with a history of grade 4 IRRs associated with obinutuzumab, for whom ritux imab was subsequently administered and no com plications occurred.
In September 2017, a 79 year old Caucasian man diagnosed with CLL in 2013 and who recently developed indications for therapy (B symptoms, symptomatic splenomegaly, and grade 3 anemia), was admitted to the Department of Hematology at the Institute of Hematology and Transfusion Medicine in Warsaw, Poland. Until hospitaliza tion, this patient had been followed by a watch and wait strategy, and since 2015 he had been receiving immunoglobulin supplementation be cause of hypogammaglobulinemia and recurrent respiratory tract infections. The patient was re ferred for a frontline therapy with O Chl due to clinically relevant comorbidities (prostate cancer, arterial hypertension, history of transient isch emic attack, and Mycobacterium tuberculosis in fection), rated at 8 points on the Cumulative Ill ness Rating Scale. This treatment was started on September 15, 2017. Despite administration of the recommended premedication and withhold ing antihypertensive treatment, he developed se vere hypotension and dyspnea immediately after obinutuzumab infusion had been started. Brady cardia and hypoxemia with impaired conscious ness were also observed. The infusion was then stopped. Full recovery was achieved after fluid re suscitation, oxygen therapy, and the administra tion of glucocorticoids and antihistamine drugs.
Since chlorambucil monotherapy was consid ered suboptimal, the patient was referred for ther apy with R Chl. The first infusion of rituximab was started 5 days later and was performed under full anesthetic monitoring. Glucocorticoids (methyl prednisolone), leukotriene receptor antagonist To the Editor Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries, including Poland. 1 Despite the increasing importance of novel agents such as B cell receptor inhibitors and Bcl 2 antago nists, immunotherapy using anti-CD20 mono clonal antibodies (MoAbs) remains an impor tant component of the current treatment of CLL.
2
The glycoengineered type II anti-CD20 MoAb obinutuzumab in combination with chlorambu cil has been approved as a frontline treatment for unfit CLL patients based on outcomes from the phase 3 CLL11 study.
3 Updated results of this trial have shown progression free survival (PFS) to be significantly prolonged with obinutuzumab and chlorambucil (O Chl) compared with a ritux imab and chlorambucil (R Chl) regimen (median PFS, 29.2 vs 15.4 months).
4 Nonetheless, thera py with obinutuzumab was associated with a con siderably higher incidence of severe grade 3 or 4 infusion related reactions (IRRs) (20% vs 4%), especially those that led to treatment discontin uation (7% vs <1%).
3
Most of the severe IRRs to obinutuzumab oc cur early, typically during the first infusion.
3 Pa tients experiencing grade 4 IRRs to obinutu zumab should discontinue infusion immedi ately and should not to be re exposed to this drug. Importantly, further optimal treatment of CLL of such patients has not been estab lished. The CLL11 study has demonstrated that continuing treatment with chlorambucil alone would clearly lead to significantly inferior PFS and overall survival. 4 However, exposure to oth er anti-CD20 MoAbs, such as rituximab, 3 ofatu mumab, 5 or ublituximab, 6 raises concerns about the unknown risk of potentially life threatening cross reactions.
Interestingly, ofatumumab, a fully humanized anti-CD20 MoAb, has been recently shown to be safely administered to a patient with thrombocy topenic purpura who presented with anaphylaxis associated with human antichimeric antibodies (montelukast), acetaminophen, and antihistamine drugs were given as premedication. The infusion was carried out without any relevant complica tions. The patient was discharged home in a stable condition, and further R Chl therapy was planned on an outpatient basis. However, due to severe Clostridium difficile infection, the patient did not continue immunochemotherapy and died several weeks later of pseudomembranous enteritis com plications and CLL progression.
LETTER TO THE EDITOR
Following this observation, we performed a ret rospective analysis based on a real life approach to CLL patients who discontinued obinutuzumab due to severe IRRs at centers of the Polish Adult Leu kemia Group. The most common strategy found was to continue chlorambucil in monotherapy. However, we identified one additional case of a pa tient with an anaphylactic reaction to obinutuzum ab who was subsequently exposed to rituximab. This was a 68 year old Caucasian man admitted to the Department of Hematology at Jagiellonian University in Kraków in October 2017 because of massive hepatomegaly and splenomegaly. He was referred for a frontline treatment with O Chl. De spite the recommended standard premedication during the first obinutuzumab dose infusion, he developed severe hypotension, dyspnea, broncho spasm, and massive sweating. Moreover, he had hypoxemia and was highly anxious. The infusion was stopped, and the patient recovered after flu id resuscitation, oxygen therapy, and administra tion of glucocorticoids and antihistamine drugs. On the next day, treatment with rituximab in com bination with bendamustine was started, preced ed by standard rituximab premedication. No clin ically relevant complications were observed. By the time of this report, the patient had complet ed 6 cycles of rituximab bendamustine therapy with no adverse events so far.
An alternative strategy for minimizing the risk of severe IRRs to anti-CD20 MoAbs, particular ly obinutuzumab, would be appropriate patient selection. However, predisposing risk factors for IRRs complicating obinutuzumab infusion are not well defined. Freeman et al 9 have shown that higher CD20 expression in CLL cells and CD16 ex pression in natural killer cells, or the presence of a palpable spleen, were associated with a great er risk of developing IRRs during treatment with obinutuzumab. When immunophenotyping data were excluded, the risk factors for IRR found were the presence of trisomy 12, splenomegaly, and baseline thrombocytopenia. In our patients, only considerable splenomegaly was observed, while none of them had baseline thrombocytopenia or trisomy of chromosome 12. Therefore, it seems rather difficult to reliably predict IRRs associated with obinutuzumab in real life clinical practice.
In conclusion, rituximab based immunoche motherapy can be safely applied in patients after obinutuzumab associated anaphylaxis. However, the existing risk of cross reactivity should be con sidered, and thus careful monitoring of such pa tients during rituximab infusion is mandatory.
